Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study

Immune checkpoint inhibitors (ICI), most commonly anti-PD-1 (programmed cell death 1) and anti-PD-L1 (programmed cell death ligand 1) therapies, have revolutionized the treatment of many cancers. ICI may activate the immune system response even in healthy tissues, which can cause immune-related adverse events (irAEs).(1) Several cases of bullous pemphigoid (BP) triggered by anti-PD-1/PD-L1 therapy have been reported.